Other equities research analysts have also recently issued research reports about the stock. ValuEngine cut shares of BioAmber from a sell rating to a strong sell rating in a report on Friday, June 2nd. Zacks Investment Research cut shares of BioAmber from a hold rating to a sell rating in a report on Monday, May 15th.
Shares of BioAmber (NYSE:BIOA) opened at 0.4782 on Monday. BioAmber has a one year low of $0.46 and a one year high of $6.50. The company’s market capitalization is $17.74 million. The stock has a 50 day moving average price of $2.15 and a 200-day moving average price of $2.58.
BioAmber (NYSE:BIOA) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.03. The business had revenue of $4.12 million during the quarter, compared to analysts’ expectations of $4.09 million. BioAmber had a negative return on equity of 56.55% and a negative net margin of 221.82%. On average, equities research analysts expect that BioAmber will post ($0.48) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This article was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://transcriptdaily.com/2017/08/13/bioamber-inc-nysebioa-given-a-3-00-price-target-at-cowen-and-company-updated-updated-updated.html.
Several large investors have recently bought and sold shares of BIOA. Robecosam AG boosted its stake in BioAmber by 3.1% in the first quarter. Robecosam AG now owns 825,000 shares of the biotechnology company’s stock worth $1,898,000 after buying an additional 25,000 shares during the last quarter. FMR LLC boosted its stake in BioAmber by 1.9% in the second quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock worth $3,495,000 after buying an additional 25,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in BioAmber by 9.9% in the second quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock worth $780,000 after buying an additional 27,278 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in BioAmber by 336.2% in the second quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock worth $139,000 after buying an additional 41,701 shares during the last quarter. Finally, TD Asset Management Inc. purchased a new stake in BioAmber during the second quarter worth approximately $977,000. Hedge funds and other institutional investors own 46.96% of the company’s stock.
BioAmber Company Profile
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
Receive News & Ratings for BioAmber Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAmber Inc. and related companies with MarketBeat.com's FREE daily email newsletter.